Baseline patient demographic and disease characteristics
| Characteristic . | Patients (n = 40) . |
|---|---|
| Age, median (range), y | 65 (39-79) |
| 18–65 y, n (%) | 21 (52.5) |
| >65 y, n (%) | 19 (47.5) |
| Male, n (%) | 22 (55.0) |
| ECOG PS, n (%) | |
| 0 | 16 (40.0) |
| 1 | 22 (55.0) |
| 2 | 2 (5.0) |
| Ann Arbor stage at study entry, n (%) | |
| I to II | 6 (15.0) |
| III to IV | 34 (85.0) |
| IPI score at study entry, n (%) | |
| 2 | 19 (47.5) |
| 3 | 15 (37.5) |
| 4 | 6 (15.0) |
| Cell of origin by local laboratory, n (%) | |
| Germinal center B cell | 17 (42.5)∗ |
| Nongerminal center B cell | 21 (52.5)† |
| Unknown | 2 (5.0) |
| Additional characterization by local laboratory, n (%) | |
| Rearrangements of MYC, BCL2, and/or BCL6 | 3 (7.5) |
| Double expressor (MYC and BCL2 overexpression without translocation) | 6 (15.0)‡ |
| None of the above | 28 (70.0) |
| Not determined/available | 3 (7.5) |
| Characteristic . | Patients (n = 40) . |
|---|---|
| Age, median (range), y | 65 (39-79) |
| 18–65 y, n (%) | 21 (52.5) |
| >65 y, n (%) | 19 (47.5) |
| Male, n (%) | 22 (55.0) |
| ECOG PS, n (%) | |
| 0 | 16 (40.0) |
| 1 | 22 (55.0) |
| 2 | 2 (5.0) |
| Ann Arbor stage at study entry, n (%) | |
| I to II | 6 (15.0) |
| III to IV | 34 (85.0) |
| IPI score at study entry, n (%) | |
| 2 | 19 (47.5) |
| 3 | 15 (37.5) |
| 4 | 6 (15.0) |
| Cell of origin by local laboratory, n (%) | |
| Germinal center B cell | 17 (42.5)∗ |
| Nongerminal center B cell | 21 (52.5)† |
| Unknown | 2 (5.0) |
| Additional characterization by local laboratory, n (%) | |
| Rearrangements of MYC, BCL2, and/or BCL6 | 3 (7.5) |
| Double expressor (MYC and BCL2 overexpression without translocation) | 6 (15.0)‡ |
| None of the above | 28 (70.0) |
| Not determined/available | 3 (7.5) |
ECOG PS, Eastern Cooperative Oncology Group performance status; GEP, gene expression profiling; IHC, immunohistochemistry.
Thirteen patients assigned based on IHC and 4 assigned based on GEP.
Seventeen patients assigned based on IHC and 4 patients based on GEP (3 had activated B cell, and 1 was unclassified).
Includes 1 patient whose double expressor status was not confirmed until after the clinical cutoff date.